Anixa Biosciences Reports Positive Phase 1 Trial Results

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potentialAnixa Biosciences ( (ANIX) ) just unveiled an announcement. On December 11, 2025, Anixa Biosciences announced positive final data from its Phase 1 clinical trial of an investigational breast cancer vaccine, presented at the 2025 San Antonio Breast Cancer Symposium. The trial, conducted with Cleveland Clinic and funded by the U.S. Department of Defense, showed the vaccine met all primary endpoints, was safe, well-tolerated, and elicited immune responses in 74% of participants. These results support the advancement to Phase 2, with plans for a combination study with Keytruda in newly diagnosed breast cancer patients. The most recent analyst rating on (ANIX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Anixa Biosciences stock, see the ANIX Stock Forecast page. Spark’s Take on ANIX Stock According to Spark, TipRanks’ AI Analyst, ANIX is a Neutral. Anixa Biosciences faces significant financial challenges, primarily due to its inability to generate revenue and persistent losses, which are compounded by negative cash flows. While its technical indicators show some positive momentum, the negative P/E ratio and lack of dividends make valuation unattractive. The company’s financial performance is the primary concern, overshadowing technical and valuation aspects. To see Spark’s full report on ANIX stock, click here. More about Anixa Biosciences Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Its therapeutic portfolio includes an ovarian cancer immunotherapy program and a range of cancer vaccines developed in collaboration with renowned research institutions like Cleveland Clinic. Anixa’s business model involves partnering with these institutions to advance emerging technologies for commercialization. Average Trading Volume: 265,574 Technical Sentiment Signal: Buy Current Market Cap: $168.9M For an in-depth examination of ANIX stock, go to TipRanks’ Overview page.